Top

Current Rheumatology Reports

Published in:

16-08-2023 | Juvenile Rheumatoid Arthritis

Treat-to-Target in Pediatric Rheumatic Diseases

Authors: Silvia Rosina, Ana Isabel Rebollo-Giménez, Alessandro Consolaro, Angelo Ravelli

Published in: Current Rheumatology Reports | Issue 11/2023

Abstract

Purpose of Review

To summarize the current evidence on the adoption of the treat-to-target (T2T) strategy in pediatric rheumatic diseases (PRD).

Recent Findings

The recent advances in the management of PRD have markedly increased the ability to achieve disease remission. Complete disease quiescence is regarded as the ideal therapeutic goal because its attainment leads to lesser long-term damage and physical disability, and to optimization of quality of life. Studies in adult rheumatic diseases have shown that patient outcomes are improved if complete suppression of the inflammatory process is aimed for by frequent adjustments of therapy according to quantitative indices. This approach, which underlies the T2T concept, has been applied in strategic trials in rheumatoid arthritis (RA). Furthermore, recommendations for the T2T have been issued for RA and other adult rheumatic diseases. There is currently a growing interest for the introduction of T2T in PRD, and recommendations for treating juvenile idiopathic arthritis (JIA) to target were promulgated. A similar initiative has been undertaken for childhood-onset systemic lupus erythematosus. Preliminary therapeutic studies have explored the T2T design in JIA.

Summary

The T2T strategy is a modern therapeutic approach that holds the promise of improving the outcomes in patients with PRD.

Lovell D, Ruperto N, Giannini E, Martini A. Advances from clinical trials in juvenile idiopathic arthritis. Nat Rev Rheumatol. 2013;9:557–63.PubMedCrossRef

Ruperto N, Martini A. Current and future perspectives in the management of juvenile idiopathic arthritis. Lancet Child Adolesc Heal. 2018;2(5):360–70.CrossRef

• Rosina S, Giancane G, Ruperto N. Emerging therapies for juvenile arthritis: agents in early clinical trials. Expert Opin Investig Drugs. 2022;31(10):1109–24. The work highlights the most recent therapeutic advances in the treatment of JIA.PubMedCrossRef

Bernatsky S, Boivin J-F, Joseph L, Manzi S, Ginzler E, Gladman DD, et al. Mortality in systemic lupus erythematosus. Arthritis Rheum. 2006;54(8):2550–7.PubMedCrossRef

Ravelli A, Trail L, Ferrari C, Ruperto N, Pistorio A, Pilkington C, et al. Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. Arthritis Care Res (Hoboken). 2010;62(1):63–72.PubMedCrossRef

Rider L, Lachenbruch P, Monroe J, Ravelli A, Cabalar I, Feldman B, et al. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. Arthritis Rheum. 2009;60(11):3425–35.PubMedPubMedCentralCrossRef

Sanner H, Kirkhus E, Merckoll E, Tollisen A, Røisland M, Lie B, et al. Long-term muscular outcome and predisposing and prognostic factors in juvenile dermatomyositis: a case-control study. Arthritis Care Res. 2010;62(8):1103–11.CrossRef

•• Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, Becker ML, Cron RQ, Feldman BM, Ferguson PJ, Gewanter H, Guzman J, Kimura Y, Lee T, Murphy K, Nigrovic PA, Ombrello MJ, Rabinovich CE, Tesher M, Twilt M, Klein-Gitelman M, Barbar-Smiley F, Cooper AM, Edelheit B, Gillispie-Taylor M, Hays K, Mannion ML, Peterson R, Flanagan E, Saad N, Sullivan N, Szymanski AM, Trachtman R, Turgunbaev M, Veiga K, Turner AS, Reston JT. 2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: recommendations for nonpharmacologic therapies, medication monitoring, immunizations, and imaging. Arthritis Care Res. 2022;74(4):505-520. American College of Rheumatology clinical practice guidelines for JIA on nonpharmacologic therapies, medication monitoring, immunizations, and imaging.

•• Onel KB, Horton DB, Lovell DJ, Shenoi S, Cuello CA, Angeles-Han ST, Becker ML, Cron RQ, Feldman BM, Ferguson PJ, Gewanter H, Guzman J, Kimura Y, Lee T, Murphy K, Nigrovic PA, Ombrello MJ, Rabinovich CE, Tesher M, Twilt M, Klein-Gitelman M, Barbar-Smiley F, Cooper AM, Edelheit B, Gillispie-Taylor M, Hays K, Mannion ML, Peterson R, Flanagan E, Saad N, Sullivan N, Szymanski AM, Trachtman R, Turgunbaev M, Veiga K, Turner AS, Reston JT. 2021 American College of Rheumatology Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis. Arthritis Care Res. 2022;74(4):521-537. American College of Rheumatology clinical practice guidelines addressing the management of oligoarthritis, temporomandibular joint arthritis and systemic juvenile idiopathic arthritis.

10.

Ringold S, Angeles-han ST, Beukelman T, Lovell D, Cuello C, Becker M, et al. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res (Hoboken). 2019;71(6):717–34.PubMedCrossRef

11.

Groot N, De Graeff N, Avcin T, Bader-Meunier B, Dolezalova P, Feldman B, et al. European evidence-based recommendations for diagnosis and treatment of paediatric antiphospholipid syndrome: The SHARE initiative. Ann Rheum Dis. 2017;76(10):1637–41.PubMedCrossRef

12.

Groot N, de Graeff N, Marks SSD, Brogan P, Avcin T, Bader-Meunier B, et al. European evidence-based recommendations for the diagnosis and treatment of childhood-onset lupus nephritis: the SHARE initiative. Ann Rheum Dis. 2017;76(12):1965–73.PubMedCrossRef

13.

Enders FB, Bader-Meunier B, Baildam E, Constantin T, Dolezalova P, Feldman BM, et al. Consensus-based recommendations for the management of juvenile dermatomyositis. Ann Rheum Dis. 2017;76(2):329–40.CrossRef

14.

Huber A, Robinson A, Reed A, Abramson L, Bout-Tabaku S, Carrasco R, et al. Consensus treatments for moderate juvenile dermatomyositis: beyond the first two months. Results of the second Childhood Arthritis and Rheumatology Research Alliance consensus conference. Arthritis Care Res (Hoboken). 2012;64(4):546–53.PubMedCrossRef

15.

Kim S, Kahn P, Robinson AB, Lang B, Shulman A, Oberle EJ, et al. Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease. Pediatr Rheumatol Online J. 2017;15(1):1.PubMedPubMedCentralCrossRef

16.

Huber AMA, Giannini E, Bowyer S, Kim S, Lang B, Lindsley C, et al. Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children’s Arthritis and Rheumatology Research Alliance Consensus Conference. Arthritis Care Res (Hoboken). 2010;62(2):219–25.PubMed

17.

Huber AM, Kim S, Reed AM, Carrasco R, Feldman BM, Hong SD, et al. Childhood arthritis and rheumatology research alliance consensus clinical treatment plans for juvenile dermatomyositis with persistent skin rash. J Rheumatol. 2017;44(1):110–6.PubMedCrossRef

18.

Ravelli A, Consolaro A, Horneff G, Laxer R, Lovell D, Wulffraat N, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2018;77(6):819–28.PubMed

19.

Tynjälä P, Vähäsalo P, Tarkiainen M, Kröger L, Aalto K, Malin M, et al. Aggressive combination drug therapy in very early polyarticular juvenile idiopathic arthritis (ACUTE-JIA): a multicentre randomised open-label clinical trial. Ann Rheum Dis. 2011;70(9):1605–12.PubMedCrossRef

20.

Wallace C, Giannini E, Spalding S, Hashkes P, O’Neil K, Zeft A, et al. Trial of early aggressive therapy in polyarticular juvenile idiopathic arthritis. Arthritis Rheum. 2012;64(6):2012–21.PubMedCrossRef

21.

Kim S, El-Hallak M, Dedeoglu F, Zurakowski D, Fuhlbrigge R, Sundel R. Complete and sustained remission of juvenile dermatomyositis resulting from aggressive treatment. Arthritis Rheum. 2009;60(6):1825–30.PubMedPubMedCentralCrossRef

22.

Bartoli M, Tarò M, Magni-Manzoni S, Pistorio A, Traverso F, Viola S, et al. The magnitude of early response to methotrexate therapy predicts long-term outcome of patients with juvenile idiopathic arthritis. Ann Rheum Dis. 2008;67(3):370–4.PubMedCrossRef

23.

Oen K, Duffy CM, Tse SML, Ramsey S, Ellsworth J, Chédeville G, et al. Early outcomes and improvement of patients with juvenile idiopathic arthritis enrolled in a Canadian multicenter inception cohort. Arthritis Care Res (Hoboken). 2010;62(4):527–36.PubMedCrossRef

24.

• Giancane G, Rosina S, Consolaro A, Ruperto N. Outcome scores in pediatric rheumatology. Curr Rheumatol Rep. 2021;23(4):23. An updated description of the main outcome measures that are available for JIA, cSLE and JDM.PubMedCrossRef

25.

• Rosina S, Tibaldi J, Mazzoni M, Bava C, Natoli V, Ravelli A. Update on outcome measures for pediatric systemic lupus erythematosus. Arthritis Care Res (Hoboken). 2020;72 Suppl 1:163–70. The paper offers a complete overview of the newest outcome scores specifically developed for use in children with cSLE.CrossRef

26.

Rider L, Aggarwal R, Machado P, Hogrel J, Reed A, Christopher-Stine L, et al. Update on outcome assessment in myositis. Nat Rev Rheumatol. 2018;14(5):303–18.PubMedPubMedCentralCrossRef

27.

Berthold E, Månsson B, Kahn R. Outcome in juvenile idiopathic arthritis: a population-based study from Sweden. Arthritis Res Ther. 2019;21(1):218.PubMedPubMedCentralCrossRef

28.

Oen K, Guzman J, Dufault B, Tucker LB, Shiff NJ, Duffy KW, et al. Health-related quality of life in an inception cohort of children with juvenile idiopathic arthritis: a longitudinal analysis. Arthritis Care Res (Hoboken). 2018;70(1):134–44.PubMedCrossRef

29.

Minden K, Niewerth M, Listing J, Biedermann T, Bollow M, Schöntube M, et al. Long-term outcome in patients with juvenile idiopathic arthritis. Arthritis Rheum. 2002;46(9):2392–401.PubMedCrossRef

30.

Smolen JS. Treat to target in rheumatology: a historical account on occasion of the 10th anniversary. Rheum Dis Clin North Am. 2019;45(4):477–85.PubMedCrossRef

31.

Sokka T, Pincus T. Rheumatoid arthritis: strategy more important than agent. Lancet (London, England). 2009;374(9688):430–2.PubMedCrossRef

32.

Smolen J, Aletaha D, Bijlsma J, Breedveld F, Boumpas D, Burmester G, et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann Rheum Dis. 2010;69(4):631–7.PubMedCrossRef

33.

Smolen J, Breedveld F, Burmester G, Bykerk V, Dougados M, Emery P, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016;75(1):3–15.PubMedCrossRef

34.

Smolen JS, Braun J, Dougados M, Emery P, Fitzgerald O, Helliwell P, et al. Treating spondyloarthritis, including ankylosing spondylitis and psoriatic arthritis, to target: recommendations of an international task force. Ann Rheum Dis. 2014;73(1):6–16.PubMedCrossRef

35.

Smolen JS, Schöls M, Braun J, Dougados M, FitzGerald O, Gladman DD, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018;77(1):3–17.PubMedCrossRef

36.

van Vollenhoven R, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2004;73(6):958–67.CrossRef

37.

Kiltz U, Smolen J, Bardin T, Cohen Solal A, Dalbeth N, Doherty M, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017;76(4):632–8.PubMedCrossRef

38.

Wollenhaupt J, Albrecht K, Krüger K, Müller-Ladner U. The new 2012 German recommendations for treating rheumatoid arthritis : differences compared to the European standpoint. Z Rheumatol. 2013;72(1):6–9.PubMedPubMedCentralCrossRef

39.

Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):685–99.PubMedCrossRef

40.

van Vollenhoven RF, Mosca M, Bertsias G, Isenberg D, Kuhn A, Lerstrøm K, et al. Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Ann Rheum Dis. 2014;73(6):958–67.PubMedCrossRef

41.

Magnani A, Pistorio A, Magni-Manzoni S, Falcone A, Lombardini G, Bandeira M, et al. Achievement of a state of inactive disease at least once in the first 5 years predicts better outcome of patients with polyarticular juvenile idiopathic arthritis. J Rheumatol. 2009;36(3):628–34.PubMedCrossRef

42.

Ramanan AV, Sage AM. Treat to Target (Drug-Free) Inactive Disease in JIA: To What Extent Is This Possible? J Clin Med. 2022;11(19):5674.PubMedPubMedCentralCrossRef

43.

Guzman J, Oen K, Tucker LB, Huber AM, Shiff N, Boire G, et al. The outcomes of juvenile idiopathic arthritis in children managed with contemporary treatments: results from the ReACCh-Out cohort. Ann Rheum Dis. 2015;74(10):1854–60.PubMedCrossRef

44.

Hinze C, Gohar F, Foell D. Management of juvenile idiopathic arthritis: hitting the target. Nat Rev Rheumatol. 2015;11(5):290–300.PubMedCrossRef

45.

Consolaro A, Negro G, Lanni S, Solari N, Martini A, Ravelli A. Toward a treat-to-target approach in the management of juvenile idiopathic arthritis. Clin Exp Rheumatol. 2012;30(4 Suppl 73):S157–62.PubMed

46.

• Gohar F, Windschall D. The new role of musculoskeletal ultrasound in the treat-to-target management of juvenile idiopathic arthritis. Rheumatol (United Kingdom). 2021;60(5):2046–53. This interesting work underlines the potential of musculoskeletal ultrasound in the adoption of T2T in JIA.

47.

Wakefield RJ, D’Agostino MA, Naredo E, Buch MH, Iagnocco A, Terslev L, et al. After treat-to-target: can a targeted ultrasound initiative improve RA outcomes? Ann Rheum Dis. 2012;71(6):799–803.PubMedCrossRef

48.

Muller PH, Brinkman DMC, Schonenberg-Meinema D, Van Den Bosch WB, Koopman-Keemink Y, Brederije ICJ, et al. Treat to target (drug-free) inactive disease in DMARD-naive juvenile idiopathic arthritis: 24-month clinical outcomes of a three-armed randomised trial. Ann Rheum Dis. 2019;78(1):51–9.CrossRef

49.

•• Klein A, Klein A, Minden K, Minden K, Hospach A, Foeldvari I, et al. Treat-to-target study for improved outcome in polyarticular juvenile idiopathic arthritis. Ann Rheum Dis. 2020;79(7):969–74. This study showed that a T2T approach was superior to routine care in treating early and active polyarticular JIA in terms of reaching a clinical remission after 12 months of treatment.PubMedCrossRef

50.

Buckley L, Ware E, Kreher G, Wiater L, Mehta J, Burnham JM. Outcome monitoring and clinical decision support in polyarticular juvenile idiopathic arthritis. J Rheumatol. 2020;47(2):273–81.PubMedCrossRef

51.

• Chang JC, Xiao R, Burnham JM, Weiss PF. Longitudinal assessment of racial disparities in juvenile idiopathic arthritis disease activity in a treat-to-target intervention. Pediatr Rheumatol Online J. 2020;18(1):88. An interesting work aimed at evaluating racial disparities in disease outcomes among children with polyarticular JIA managed according to a T2T strategy.PubMedPubMedCentralCrossRef

52.

• Schoemaker CG, Swart JF. Wulffraat NM Treating juvenile idiopathic arthritis to target: What is the optimal target definition to reach all goals? Pediatr Rheumatol. 2020;18(1):7–10. A stimulating commentary about the T2T recommendations for JIA.CrossRef

53.

Carpenter L, Barnett R, Mahendran P, Nikiphorou E, Gwinnutt J, Verstappen S, et al. Secular changes in functional disability, pain, fatigue and mental well-being in early rheumatoid arthritis. A longitudinal meta-analysis. Semin Arthritis Rheum. 2020;50(2):209–19.PubMedCrossRef

54.

Almeida C, Choy EHS, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane database Syst Rev. 2016;2016(6):CD008334.PubMedPubMedCentral

55.

Shiff NJ, Tupper S, Oen K, Guzman J, Lim H, Lee CH, et al. Trajectories of pain severity in juvenile idiopathic arthritis: results from the Research in Arthritis in Canadian Children Emphasizing Outcomes cohort. Pain. 2018;159(1):57–66.PubMedCrossRef

56.

• Schoemaker CG, de Wit MPT. Treat-to-target from the patient perspective is bowling for a perfect strike. Arthritis Rheumatol. 2021;73(1):9–11. The article offers interesting insights on patients’ perspective about T2T in rheumatic diseases.PubMedCrossRef

57.

Ferreira RJO, Duarte C, Ndosi M, de Wit M, Gossec L, da Silva JAP. Suppressing inflammation in rheumatoid arthritis: does patient global assessment blur the target? A practice-based call for a paradigm change. Arthritis Care Res (Hoboken). 2018;70(3):369–78.PubMedCrossRef

58.

•• Rosina S, Natoli V, Santaniello S, Trincianti C, Consolaro A, Ravelli A. Novel biomarkers for prediction of outcome and therapeutic response in juvenile idiopathic arthritis. Expert Rev Clin Immunol. 2021;17(8):853–70. The paper provides a wide overview of the newest biomarkers specifically developed for the prediction of outcome and therapeutic response in JIA.PubMedCrossRef

59.

•• Mannion ML, Cron RQ. Therapeutic strategies for treating juvenile idiopathic arthritis. Curr Opin Pharmacol [Internet]. 2022;64:102226. https://doi.org/10.1016/j.coph.2022.102226. A detailed review about common treatment strategies in JIA, with a main focus on biologic medications and small molecule inhibitors.CrossRefPubMed

60.

Burrone M, Mazzoni M, Naddei R, Pistorio A, Spelta M, Scala S, et al. Looking for the best strategy to treat children with new onset juvenile idiopathic arthritis: presentation of the “comparison of STep-up and step-down therapeutic strategies in childhood ARthritiS” (STARS) trial. Pediatr Rheumatol [Internet]. 2022;20(1):1–10. https://doi.org/10.1186/s12969-022-00739-x.CrossRef

61.

•• El Tal T, Ryan ME, Feldman BM, Bingham CA, Burnham JM, Batthish M, et al. Consensus approach to a treat-to-target strategy in juvenile idiopathic arthritis care: report from the 2020 PR-COIN consensus conference. J Rheumatol. 2022;49(5):497–503. The paper reports the results of a consensus conference held by a collaborative learning health network with the aim of gaining feedback from centers experienced in testing the T2T interventions in their local clinical settings.PubMedCrossRef

62.

Lipstein EA, Brinkman WB, Britto MT. What is known about parents’ treatment decisions? A narrative review of pediatric decision making. Med Decis Mak an Int J Soc Med Decis Mak. 2012;32(2):246–58.CrossRef

63.

El Miedany Y, El Gaafary M, Lotfy H, El Aroussy N, Mekkawy D, Nasef SI, et al. Shared decision-making aid for juvenile idiopathic arthritis: moving from informative patient education to interactive critical thinking. Clin Rheumatol. 2019;38(11):3217–25.PubMedCrossRef

64.

Klein-Gitelman M, Lane J. Systemic lupus erythematosus. In: Petty R, Laxer R, Lindsey C, Wedderburn L, editors. Textbook of Pediatric Rheumatology. 7th ed. Philadelphia, PA: Elsevier Saunders; 2016. p. 285–317.CrossRef

65.

Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008;58(2):556–62.PubMedCrossRef

66.

Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, et al. Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2009;61(1):13–20.PubMedPubMedCentralCrossRef

67.

Mina R, Brunner HI. Pediatric lupus–are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am. 2010;36(1):53–80 (vii–viii).PubMedPubMedCentralCrossRef

68.

Tucker LB, Uribe AG, Fernández M, Vilá LM, McGwin G, Apte M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008;17(4):314–22.PubMedPubMedCentralCrossRef

69.

Brunner H, Feldman B, Bombardier C, Silverman E. Sensitivity of the Systemic Lupus Erythematosus Disease Activity Index, British Isles Lupus Assessment Group Index, and Systemic Lupus Activity Measure in the evaluation of clinical change in childhood-onset systemic lupus erythematosus. Arthritis Rheum. 1999;42(7):1354–60.PubMedCrossRef

70.

Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA. Differences in disease phenotype and severity in SLE across age groups. Lupus. 2016;25(14):1542–50.PubMedPubMedCentralCrossRef

71.

Brunner HI, Higgins GC, Wiers K, Lapidus SK, Olson JC, Onel K, et al. Health-related quality of life and its relationship to patient disease course in childhood-onset systemic lupus erythematosus. J Rheumatol. 2009;36(7):1536–45.PubMedCrossRef

72.

Lythgoe H, Smith EMD, Killeen OG, Murphy R, Pilkington C, Pain CE, et al. Prospective epidemiological study of juvenile-onset systemic lupus erythematosus in the UK and Republic of Ireland. Rheumatology (Oxford). 2022;61(10):4097–106.PubMedCrossRef

73.

Groot N, Shaikhani D, Teng YKO, de Leeuw K, Bijl M, Dolhain RJEM, et al. Long-term clinical outcomes in a cohort of adults with childhood-onset systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ). 2019;71(2):290–301.CrossRef

74.

Kandane-Rathnayake R, Louthrenoo W, Hoi A, Luo S-F, Wu Y-JJ, Chen Y-H, et al. “Not at target”: prevalence and consequences of inadequate disease control in systemic lupus erythematosus-a multinational observational cohort study. Arthritis Res Ther. 2022;24(1):70.PubMedPubMedCentralCrossRef

75.

Golder V, Kandane-Rathnayake R, Hoi AY-B, Huq M, Louthrenoo W, An Y, et al. Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective study. Arthritis Res Ther. 2017;19(1):62.PubMedPubMedCentralCrossRef

76.

•• Smith EMD,Aggarwal A, Ainsworth J,Al-Abadi E,Avcin T, Bortey L, Burnham J, Ciurtin C, Hedrich CM, Kamphuis S, Levy DM, Lewandowski LB, Maxwell N, Morand EF, Ozen S, Pain CE, Ravelli A, Saad Magalhaes C, Pilkington CA, Schonenberg-Meinema D, Scott C, Tullus K, Beresford MW. cSLE T2T International Task Force.Towards development of treat to target (T2T) in childhood-onset systemic lupus erythematosus:PReS-endorsed overarching principles and points-to-consider from an international task force. Ann Rheum Dis 2023;82(6):788-798. The article describes a set of consensus agreed overarching principles and points-to-consider for T2T in cSLE developed by an international Task Force.

77.

•• Smith EMD, Tharmaratnam K, Al-Abadi E, Armon K, Bailey K, Brennan M, et al. Attainment of low disease activity and remission targets reduces the risk of severe flare and new damage in childhood lupus. Rheumatology (Oxford). 2022;61(8):3378–89. The study demonstrated that definitions of LDA/remission derived from adult SLE are attainable in cSLE and that their achievement is associated with lower risk of severe flare and damage accrual.PubMedCrossRef

78.

Ozturk K, Caglayan S, Tanatar A, Baglan E, Yener Otar G, Kavrul Kayaalp G, et al. Low disease activity state in juvenile-onset systemic lupus erythematosus. Lupus. 2021;30(13):2144–50.PubMedCrossRef

79.

• Wahadat MJ, Van Den Berg L, Timmermans D, Van Rijswijk K, Van Dijk-Hummelman A, Bakx S, et al. LLDAS is an attainable treat-to-target goal in childhood-onset SLE. Lupus Sci Med. 2021;8(1):1–5. This prospective study showed that LLDAS can be reached in cSLE in a median of 6 months and that the majority of patients remain in LLDAS >50% of time.CrossRef

80.

Na Nakorn K, Piyaphanee N, Sukharomana M, Pinpatanapong R, Charuvanij S. Outcomes of achieving lupus low disease activity state and damage accrual in childhood-onset systemic lupus erythematosus. Clin Rheumatol [Internet]. 2023;(0123456789). Available from: https://doi.org/10.1007/s10067-023-06533-8

81.

• Qiu S, Zhang H, Yu S, Yang Q, Zhang G, Yang H, et al. Clinical manifestations, prognosis, and treat-to-target assessment of pediatric lupus nephritis. Pediatr Nephrol. 2022;37(2):367–76. A retrospective study on a monocentric cohort of 220 patients with lupus nephritis in which clinical manifestations, renal pathological characteristics, and the factors associated with poor prognosis were analyzed.PubMedCrossRef

82.

Franklyn K, Lau CS, Navarra SV, Louthrenoo W, Lateef A, Hamijoyo L, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis. 2016;75(9):1615–21.PubMedCrossRef

83.

• Kisaoglu H, Baba O, Kalyoncu M. Lupus low disease activity state as a treatment target for pediatric patients with lupus nephritis. Pediatr Nephrol [Internet]. 2023;38(4):1167–75. https://doi.org/10.1007/s00467-022-05742-8. A retrospective study on 24 children with lupus nephritis that showed that LLDAS is an achievable treatment target and is associated with lower rates of kidney flare and damage.CrossRefPubMed

84.

Vollbach K, Schuetz C, Hedrich CM, Speth F, Mönkemöller K, Brunner J, et al. Working towards a treat-to-target protocol in juvenile proliferative lupus nephritis – a survey of pediatric rheumatologists and nephrologists in Germany and Austria. Front Pediatr. 2022;10(April):1–12.

85.

•• Smith EMD, Aggarwal A, Ainsworth J, Al-Abadi E, Avcin T, Bortey L, et al. PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS). Clin Immunol. 2023;250(March):109296. A very useful work reporting the PReS-endorsed definition of childhood lupus low disease activity state.PubMedCrossRef

86.

• Smith EMD, Gorst SL, Al-Abadi E, Hawley DP, Leone V, Pilkington C, et al. “It is good to have a target in mind”: qualitative views of patients and parents informing a treat to target clinical trial in juvenile-onset systemic lupus erythematosus. Rheumatol (United Kingdom). 2021;60(12):5630–41. This interesting paper explores patient and parental views on T2T targets and study design in cSLE.

87.

Feldman B, Rider L, Reed A, Pachman L. Juvenile dermatomyositis and other idiopathic inflammatory myopathies of childhood. Lancet. 2008;371(9631):2201–12.PubMedCrossRef

88.

Rosina S, Varnier G, Mazzoni M, Lanni S, Malattia C, Ravelli A. Innovative research design to meet the challenges of clinical trials for juvenile dermatomyositis. Curr Rheumatol Rep. 2018;20(5):29.PubMedCrossRef

89.

Stringer E, Bohnsack J, Bowyer SL, Griffin TA, Huber AM, Lang B, et al. Treatment approaches to juvenile dermatomyositis (JDM) across North America: the Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM treatment survey. J Rheumatol. 2010;37(9):1953–61.PubMedCrossRef

90.

Hinze CH, Speth F, Oommen PT, Haas J-P. Current management of juvenile dermatomyositis in Germany and Austria: an online survey of pediatric rheumatologists and pediatric neurologists. Pediatr Rheumatol Online J. 2018;16(1):38.PubMedPubMedCentralCrossRef

91.

Tollisen A, Sanner H, Flatø B, Wahl A. Quality of life in adults with juvenile-onset dermatomyositis: a case-control study. Arthritis Care Res (Hoboken). 2012;64(7):1020–7.PubMed

92.

Sanner H, Gran J-T, Sjaastad I, Flatø B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. Rheumatology (Oxford). 2009;48(12):1541–7.PubMedCrossRef

93.

Boros C, McCann L, Simou S, Cancemi D, Ambrose N, Pilkington CA, et al. Juvenile Dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective. Pediatr Rheumatol Online J. 2022;20(1):102.PubMedPubMedCentralCrossRef

94.

Ruperto N, Pistorio A, Oliveira S, Zulian F, Cuttica R, Ravelli A, et al. Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. Lancet. 2016;387(10019):671–8.PubMedCrossRef

95.

Oddis C, Reed A, Aggarwal R, Rider L, Ascherman D, Levesque M, et al. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial. Arthritis Rheum. 2013;65(2):314–24.PubMedPubMedCentralCrossRef

96.

Ramanan AV, Campbell-Webster N, Ota S, Parker S, Tran D, Tyrrell PN, et al. The effectiveness of treating juvenile dermatomyositis with methotrexate and aggressively tapered corticosteroids. Arthritis Rheum. 2005;52(11):3570–8.PubMedCrossRef

97.

Hinze CH, Oommen PT, Dressler F, Urban A, Weller-Heinemann F, Speth F, et al. Development of practice and consensus-based strategies including a treat-to-target approach for the management of moderate and severe juvenile dermatomyositis in Germany and Austria. Pediatr Rheumatol. 2018;16(1):1–9.CrossRef

98.

Abu-Zaid MH, Salah S, Lotfy HM, El Gaafary M, Abdulhady H, Tabra SAA, Salah H, Farag Y, Eissa M, Maher SE, Radwan A, El-Shanawany AT, Medhat BM, El Mikkawy D, Mosad Mosa D, El Deriny G, Mortada M, Osman NS, Fouad NA, Elkaraly NE, Mohamed SS, Hassan WA, Amer YA, Nasef SI, El Miedany Y. Consensus evidence-based recommendations for treat-to-target management of immunoglobulin A vasculitis. Ther Adv Musculoskelet Dis. 2021;13:1759720X211059610

Title: Treat-to-Target in Pediatric Rheumatic Diseases
Authors: Silvia Rosina
Ana Isabel Rebollo-Giménez
Alessandro Consolaro
Angelo Ravelli
Publication date: 16-08-2023
Publisher: Springer US
Keywords: Juvenile Rheumatoid Arthritis
Juvenile Rheumatoid Arthritis
Juvenile Dermatomyositis
Rheumatoid Arthritis
Published in: Current Rheumatology Reports / Issue 11/2023
Print ISSN: 1523-3774
Electronic ISSN: 1534-6307
DOI: https://doi.org/10.1007/s11926-023-01112-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials